Depresszió: vizsgálatok itt: Magyarország
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 13.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Where
- Budapest, Budapest III
- Életkor
- 18 év to 65 év
- People
- 360 worldwide
- Run by
- Seaport Therapeutics
See details and how to joinNCT07065240 · EU 2025-521240-37-00 - 2. fázisCsak meghívásosAn Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
- Where
- Budapest, Budapest III, Pécs
- Életkor
- 18 év to 66 év
- People
- 360 worldwide
- Run by
- Seaport Therapeutics
See details and how to joinNCT07161700 · EU 2025-522347-18-00 - 2. fázisNot yet taking people in MagyarországA Study of Brenipatide in Participants With Major Depressive Disorder
- Where
- Budapest, Gyöngyös
- Életkor
- 18 év to 75 év
- People
- 330 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07928245 · EU 2026-527689-65-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Where
- Budapest, Debrecen, Győr, Szeged
- Életkor
- 12 év to 17 év
- People
- 258 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07227454 · EU 2024-518615-19-00 - 3. fázisTaking peopleLong-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Where
- Budapest, Budapest III, Gyongyos, Kalocsa
- Életkor
- 18 év and over
- People
- 850 worldwide
- Run by
- Neurocrine Biosciences
See details and how to joinNCT06966401 · EU 2024-519423-24-00 - 3. fázisTaking peopleNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Where
- Budapest, Budapest III, Gyongyos, Kalocsa
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Neurocrine Biosciences
See details and how to joinNCT06963021 · EU 2024-519421-37-00 - 4. fázisNot yet taking people in MagyarországEvaluation of the efficacy of Trazodone in improving emotional blunting symptoms in Patients with Major Depressive Disorder
- Where
- Gyongyos, Pécs
- Életkor
- 18 év to 64 év
- People
- 120 worldwide
- Run by
- Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
See details and how to join2025-523267-38-00 - No phaseCsak meghívásosEffect of Theta-burst rTMS Therapy on the Clinical and Cognitive Symptoms of Patients With Therapy Resistant Depression and Response Prediction With Neuroimaging Methods.
- Where
- Budapest
- Életkor
- 18 év and over
- People
- 54
- Run by
- Semmelweis University
See details and how to joinNCT07207239